R3 Vascular Inc. today announced closing of its Series A financing round, including new equity investments of $15 million and the conversion of $2.8 million of convertible notes. The round was led by an unnamed corporate investor and 415 CAPITAL, with participation from HBM-MedFocus LLC and Wexford Capital. Proceeds will support the company's clinical trial work in developing a next generation of below-the-knee (BTK) interventional therapies for PAD.


AccelFoods is an early-stage venture fund investing in consumer products. 
We partner with entrepreneurs to bring innovative, high-quality food and 
beverage products to the forefront of the industry and create the next 
generation of enduring brands. With nearly $40m under management, we are 
hands-on partners that work tactically with our founders to scale their 
businesses quickly and smartly. We connect the dots within the broader food 
& beverage ecosystem to provide unique access, share distinct expertise, 
and build solid infrastructure.

R3 Vascular Inc. Completes Series A Financing

Description

Company Information

Related People